GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Tucaresol As Add-On To HAART (Highly Active Antiretroviral Therapy) In Chronic HIV-1 Infected Adults
- Conditions
- HIV Infection
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2008-10-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 45
- Registration Number
- NCT00343941
- Locations
- 🇮🇹
GSK Investigational Site, Padova, Veneto, Italy
AUGMENTIN 1gm In Skin And Soft Tissue Infection
- Conditions
- Infection, Soft TissueSkin Diseases, Infectious
- Interventions
- First Posted Date
- 2006-06-22
- Last Posted Date
- 2012-11-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 195
- Registration Number
- NCT00343135
- Locations
- 🇵🇰
GSK Investigational Site, Lahore, Pakistan
Pharmacokinetic Study Of Valaciclovir Hydrochloride Tablets
- Conditions
- Virus Diseases
- First Posted Date
- 2006-06-22
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT00343278
Clinical Utility Of Genetic Screening For HLA-B*5701, On Susceptibility To Abacavir Hypersensitivity
- Conditions
- HIV Infection
- First Posted Date
- 2006-06-21
- Last Posted Date
- 2010-01-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1806
- Registration Number
- NCT00340080
- Locations
- 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
- Conditions
- Hepatitis A
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 240
- Registration Number
- NCT00338351
- Locations
- 🇨🇱
GSK Investigational Site, Santiago, Región Metro De Santiago, Chile
The Efficacy And Safety Of Lacidipine And Amlodipine Once-Daily Treatment In Hypertensive Adult Patients
- Conditions
- HypertensionEssentialUncomplicated Hypertension
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2017-10-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 70
- Registration Number
- NCT00338338
- Locations
- 🇨🇳
GSK Investigational Site, Taipei, Taiwan
Pharmacokinetic Study Of EPZICOM Tablet
- Conditions
- HIV Infection
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 8
- Registration Number
- NCT00337922
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women
- Conditions
- Papillomavirus Type 16/18 InfectionCervical Intraepithelial Neoplasia
- Interventions
- Biological: Cervarix™
- First Posted Date
- 2006-06-16
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 770
- Registration Number
- NCT00337818
- Locations
- 🇪🇪
GSK Investigational Site, Tallinn, Estonia
Persistence of the Immune Response to Hepatitis B in 4-6 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib
- Conditions
- Hepatitis B
- First Posted Date
- 2006-06-12
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 300
- Registration Number
- NCT00335881
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers Disease
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2013-01-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT00334568
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom